. Histopathological examination of liver, kidney, heart and brain samples of vehicle, 21b (10 mg/kg), 21e (10 mg/kg) and sorafenib (10 mg/kg)-treated EAC solid tumor bearing mice (40x). Vehicle and 10 mg/kg 21b treated EAC solid tumor bearing mice showed congested central hepatic vein and focally degenerated hepatocytes alongside with normal renal histoarchitecture. Congested myocardial blood vessels and neuronal degeneration were also noticed in hippocampus. 10 mg/kg 21e treated group also showed congested myocardial blood vessels without any histopathological alterations in liver, kidney and brain specimens of treated mice. Degenerative changes were found in the hepatocytes and hippocampus of 10 mg/kg sorafenib treated EAC solid tumor bearing mice together with normal renal and cardiac histoarchitecture.
Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents
. Histopathological examination of liver, kidney, heart and brain samples of vehicle, 21b (10 mg/kg), 21e (10 mg/kg) and sorafenib (10 mg/kg)-treated EAC solid tumor bearing mice (40x). Vehicle and 10 mg/kg 21b treated EAC solid tumor bearing mice showed congested central hepatic vein and focally degenerated hepatocytes alongside with normal renal histoarchitecture. Congested myocardial blood vessels and neuronal degeneration were also noticed in hippocampus. 10 mg/kg 21e treated group also showed congested myocardial blood vessels without any histopathological alterations in liver, kidney and brain specimens of treated mice. Degenerative changes were found in the hepatocytes and hippocampus of 10 mg/kg sorafenib treated EAC solid tumor bearing mice together with normal renal and cardiac histoarchitecture. 14a  14b  14e  15d  15i  20a  20c  20d  21a  21b  21c  21d 1-(3-Chloro-4-methylphenyl)-3-(4-nitrophenyl)urea (7f):
The titled compound was separated as white crystals ( 
1-(4-Aminophenyl)-3-(m-tolyl)urea (8b):
The titled compound was separated as greyish pink crystals (0.75 g, 75%); m. 
1-(4-Aminophenyl)-3-(3-methoxyphenyl)urea (8c):
The titled compound was separated as white crystals (0.64 g, 72%); m.p. 164 
1-(4-Aminophenyl)-3-(3-chlorophenyl)urea (8d):
The titled compound was separated as buff crystals (0.68 g, 76%); m. 
1-(3-Acetylphenyl)-3-(4-aminophenyl)urea (8g):
The titled compound was separated as white crystals (0.675 g, 75%); m. 
1-(4-Aminophenyl)-3-(4-ethylphenyl)urea (8i):
The titled compound was separated as white crystals (0.75 g, 75%); m. Hz, 2H, Ph-CH 2 CH 3 ), 1.30 (t, J = 6.9 Hz, 3H, Ph-CH 2 CH 3 ).
1-(4-Hydroxyphenyl)-3-(3-methoxyphenyl)urea (9c):
The titled compound was separated as brown crystals (1.39 g, 85%); m. 
Ethyl 4-[(4-((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)amino]-6-methylfuro[2,3-d]pyrimidine-5-carboxylate (14d):
The titled compound was collected by filtration, washed with hot ethanol, allowed to dry and recrystallized from THF to give compound (14d) as yellowish white crystals (0.33 g, 60%); 
Ethyl 6-methyl-4-[(4-(3-phenylureido)phenyl)amino]furo[2,3-d]pyrimidine-5-carboxylate (15a):
The titled compound was separated as white crystals (0.26 g, 60%); m. 
Ethyl 4-[(4-(3-(3-chloro-4-methylphenyl)ureido)phenyl)amino]-6-methylfuro[2,3-d]pyrimidine-5-carboxylate (15f):
The titled compound was separated as white crystals (0.247 g, 50%); m. 
Ethyl 4-[4-(3-(3-methoxyphenyl)ureido)phenoxy]-6-methylfuro[2,3-d]pyrimidine-5-carboxylate (16c):
The titled compound was separated as buff crystals (0.403 g, 80%); m. 
Ethyl 4-[4-(3-(4-chlorophenyl)ureido)phenoxy]-6-methylfuro[2,3-d]pyrimidine-5-carboxylate (16d):
The 
Ethyl 4-[4-(3-(3-chloro-4-methylphenyl)ureido)phenoxy]-6-methylfuro[2,3-d]pyrimidine-5-carboxylate (16e):
The titled compound was separated as brown crystals (0.249 g, 55%); m. 
1-phenyl-3-(4-[(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)amino]phenyl)urea (20a):
The titled compound was separated as brown crystals (0.11 g, 25%); m. 
1-(3-Chlorophenyl)-3-(4-[(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-

4-yl)amino]phenyl)urea (20d):
The titled compound was separated as buff crystals (0.123 g, 28%); m. 
1-(3-Chloro-4-methylphenyl)-3-(4-[(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)amino]phenyl)urea (20f):
The titled compound was separated as buff crystals (0.109 g, 23%); m. The titled compound was separated as grey crystals (0.306 g, 72%); m. 
Biological Evaluation assay In vitro VEGFR-2 tyrosine kinase activity Assay protocol
The assay was performed using Kinase-Glo Plus luminescence kinase assay kit (Promega). was added to each reaction and incubate the plate for 5 minutes at room temperature.
Luminescence signal was measured using a BioTek Synergy 2 microplate reader. VEGFR activity assays were performed in duplicate at each concentration.
Data analysis
The luminescence data were analyzed using the computer software, Graphpad Prism 
In vitro multiple-kinase inhibition assay Assay protocol
The assay was performed using the same conditions for VEGFR-2 activity assay (section 5.2.1.1). The assays for c-Kit was an exception, it was performed using ADP-Glo Kinase assay reagents (Promega). Luminescence signal was measured using a BioTek Synergy 2 microplate reader
Data analysis
The luminescence data were analyzed using the same computer software and the same protocol 
Cell proliferation assays were performed in triplicate at each concentration. The fluorescent intensity data were analyzed using the computer software, Graphpad Prism. In the absence of the compound, the fluorescent intensity (F t ) in each data set was defined as 100%. In the absence of cells, the fluorescent intensity (F b ) in each data set was defined as 0%. The percent cell in the presence of each compound was calculated according to the following equation: %cell = (F- 
